212 related articles for article (PubMed ID: 22941213)
1. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Eum KH; Ahn SK; Kang H; Lee M
Mol Cell Biochem; 2013 Jan; 372(1-2):65-74. PubMed ID: 22941213
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
3. The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts.
Ahn JH; Ahn SK; Lee M
Biochem Biophys Res Commun; 2012 Jan; 417(2):857-63. PubMed ID: 22206679
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
Wei G; Wang M; Carr BI
J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
[TBL] [Abstract][Full Text] [Related]
5. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
7. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
9. Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
Du W; Zhou JR; Wang DL; Gong K; Zhang QJ
World J Surg Oncol; 2012 Apr; 10():60. PubMed ID: 22520038
[TBL] [Abstract][Full Text] [Related]
10. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
Yu P; Ye L; Wang H; Du G; Zhang J; Zhang J; Tian J
Tumour Biol; 2015 Mar; 36(3):2143-53. PubMed ID: 25398692
[TBL] [Abstract][Full Text] [Related]
11. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
12. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
Dudgeon C; Peng R; Wang P; Sebastiani A; Yu J; Zhang L
Oncogene; 2012 Nov; 31(46):4848-58. PubMed ID: 22286758
[TBL] [Abstract][Full Text] [Related]
14. Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2.
Ahn JH; Lee M
Cancer Lett; 2011 Nov; 310(2):188-97. PubMed ID: 21775053
[TBL] [Abstract][Full Text] [Related]
15. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
18. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
19. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
20. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]